Details of the Drug Combinations

General Information of This Drug (ID: DMVXBSW)

Drug Name

BTZ-043 DMVXBSW

Synonyms

BTZ043; 1161233-85-7; BTZ-043; BTZ-10526043; UNII-G55ZH52P57; 2-[(3S)-3-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one; Bzt043; MMV676603; SCHEMBL2488829; (S)-2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one; 4H-1,3-Benzothiazin-4-one, 2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-; G55ZH52P57; 2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one; BTZ 043; GTUIRORNXIOHQR-VIFPVBQESA-N; 4H-1,3-BENZOTHIAZIN-4-ONE, 2-((2S)-2-METHYL-1,4-DIOXA-8-AZASPIRO(4.5)DEC-8-YL)-8-NITRO-6-(TRIFLUOROMETHYL)-; BTZ043-racemate; S1097_Selleck; PBTZ 169; CHEMBL1822872; GTPL13034; DTXSID80151286; BCPP000312; EX-A1012; MFCD17215196; AKOS030526000; BCP9000457; CS-5635; AC-35368; AS-74893; BTZ 10526043; HY-13579; EN300-23853592; Q27278777; [2-[(3S)-3-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]-4-oxo-6-(trifluoromethyl)-1,3-benzothiazin-8-yl]azinic acid; 2-((2S)-2-METHYL-1,4-DIOXA-8-AZASPIRO(4.5)DECAN-8-YL)-8-NITRO-6-TRIFLUOROMETHYL-4H-1,3-BENZOTHIAZIN-4-ONE

Indication

Disease Entry	ICD 11	Status	REF
Tuberculosis	1B10-1B14	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
BTZ-043 + Idarubicin	DC5NB67	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04044001) A Prospective Phase Ib/IIa, Active-controlled, Randomized, Open-label Study to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Multiple Oral Doses of BTZ-043 Tablets in Subjects With Newly Diagnosed, Uncomplicated, Smear-positive, Drug-susceptible Pulmonary Tuberculosis. U.S.National Institutes of Health.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.